Test Code HIAA 5-Hydroxyindoleacetic Acid, 24 Hour, Urine
Reporting Name
5-Hydroxyindoleacetic Acid, UUseful For
Biochemical diagnosis and monitoring of intestinal carcinoid syndrome using 24-hour urine specimens
Performing Laboratory
Mayo Clinic Laboratories in RochesterSpecimen Type
UrineOrdering Guidance
This test is the preferred test for measurement of 5-hydroxyindoleacetic acid concentrations. If a random urine collection is preferred, order HIAAR / 5-Hydroxyindoleacetic Acid, Random, Urine.
Necessary Information
1. Collection duration and urine volume in milliliters are required.
2. Patient's age and sex are required.
Specimen Required
Patient Preparation:
1. Some medications could interfere with test results. The ordering provider should decide if any medications should be stopped and when they should be restarted. If clinically feasible, discontinue the following medications at least 48 hours prior to, as well as during, specimen collection:
-Acetaminophen (Tylenol or generic versions)
-Tryptophan containing supplements
2. For 48 hours prior to, as well as during, the urine collection, the patient should:
Limit the following to one serving per day:
-Fruits
-Vegetables
-Nuts
-Caffeinated beverages or foods
Supplies: Urine Tubes, 10 mL (T068)
Container/Tube: Plastic, 10-mL urine tube
Specimen Volume: 5 mL
Collection Instructions:
1. Add 25 mL of 50% acetic acid as preservative at start of collection. Use 15 mL of 50% acetic acid for children <5 years old.
2. Collect a 24-hour urine specimen.
Additional Information: See Urine Preservatives-Collection and Transportation for 24-Hour Urine Specimens for multiple collections.
Specimen Minimum Volume
1 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Urine | Refrigerated (preferred) | 56 days | |
Frozen | 365 days |
Special Instructions
Reference Values
5-HIAA, mg/24 hour 99th percentile cutoff |
||
Age |
Female |
Male |
≤23 months |
≤2.7 |
≤2.3 |
24-35 months |
≤3.0 |
≤2.6 |
3 years |
≤3.2 |
≤2.9 |
4 years |
≤3.4 |
≤3.2 |
5 years |
≤3.6 |
≤3.6 |
6 years |
≤3.8 |
≤3.9 |
7 years |
≤4.0 |
≤4.2 |
8 years |
≤4.2 |
≤4.5 |
9 years |
≤4.5 |
≤4.8 |
10 years |
≤4.7 |
≤5.1 |
11 years |
≤4.9 |
≤5.3 |
12 years |
≤5.2 |
≤5.6 |
13 years |
≤5.4 |
≤5.8 |
14 years |
≤5.6 |
≤6.1 |
15 years |
≤5.7 |
≤6.3 |
16 years |
≤5.9 |
≤6.4 |
17 years |
≤6.0 |
≤6.6 |
18 years |
≤6.0 |
≤6.7 |
19 years |
≤6.1 |
≤6.8 |
20 years |
≤6.1 |
≤6.9 |
21 years |
≤6.2 |
≤6.9 |
22 years |
≤6.2 |
≤7.0 |
23 years |
≤6.2 |
≤7.0 |
24 years |
≤6.3 |
≤7.1 |
25 years |
≤6.3 |
≤7.2 |
26 years |
≤6.3 |
≤7.2 |
27 years |
≤6.4 |
≤7.3 |
28 years |
≤6.4 |
≤7.4 |
29 years |
≤6.5 |
≤7.5 |
30 years |
≤6.6 |
≤7.5 |
31 years |
≤6.6 |
≤7.6 |
32 years |
≤6.7 |
≤7.7 |
33 years |
≤6.8 |
≤7.7 |
34 years |
≤6.8 |
≤7.8 |
35 years |
≤6.9 |
≤7.9 |
36 years |
≤6.9 |
≤7.9 |
37 years |
≤7.0 |
≤8.0 |
38 years |
≤7.0 |
≤8.1 |
39 years |
≤7.0 |
≤8.2 |
40 years |
≤7.1 |
≤8.2 |
41 years |
≤7.1 |
≤8.3 |
42 years |
≤7.2 |
≤8.4 |
43 years |
≤7.3 |
≤8.5 |
44 years |
≤7.4 |
≤8.6 |
45 years |
≤7.4 |
≤8.7 |
46 years |
≤7.5 |
≤8.8 |
47 years |
≤7.6 |
≤8.9 |
48 years |
≤7.6 |
≤9.0 |
49 years |
≤7.7 |
≤9.1 |
50 years |
≤7.7 |
≤9.2 |
51 years |
≤7.8 |
≤9.3 |
52 years |
≤7.8 |
≤9.4 |
53 years |
≤7.9 |
≤9.5 |
54 years |
≤8.0 |
≤9.6 |
55 years |
≤8.1 |
≤9.7 |
56 years |
≤8.1 |
≤9.7 |
57 years |
≤8.2 |
≤9.8 |
58 years |
≤8.3 |
≤9.8 |
59 years |
≤8.3 |
≤9.8 |
60 years |
≤8.3 |
≤9.9 |
61 years |
≤8.3 |
≤9.9 |
62 years |
≤8.4 |
≤9.9 |
63 years |
≤8.4 |
≤10.0 |
64 years |
≤8.4 |
≤10.0 |
65 years |
≤8.4 |
≤10.0 |
66 years |
≤8.5 |
≤10.1 |
67 years |
≤8.5 |
≤10.1 |
68 years |
≤8.5 |
≤10.1 |
69 years |
≤8.5 |
≤10.2 |
70 years |
≤8.5 |
≤10.2 |
71 years |
≤8.6 |
≤10.2 |
72 years |
≤8.6 |
≤10.2 |
73 years |
≤8.5 |
≤10.1 |
74 years |
≤8.5 |
≤10.1 |
75 years |
≤8.6 |
≤10.1 |
76 years |
≤8.6 |
≤10.0 |
77 years |
≤8.6 |
≤10.0 |
78 years |
≤8.6 |
≤10.0 |
79 years |
≤8.6 |
≤10.0 |
80 years |
≤8.7 |
≤9.9 |
81 years |
≤8.7 |
≤9.9 |
82 years |
≤8.7 |
≤9.9 |
83 years |
≤8.7 |
≤9.9 |
84 years |
≤8.7 |
≤9.9 |
85 years |
≤8.6 |
≤9.8 |
86 years |
≤8.5 |
≤9.8 |
87 years |
≤8.4 |
≤9.7 |
88 years |
≤8.3 |
≤9.7 |
89 years |
≤8.1 |
≤9.5 |
90 years |
≤7.9 |
≤9.4 |
91 years |
≤7.6 |
≤9.2 |
92 years |
≤7.4 |
≤9.0 |
93 years |
≤7.1 |
≤8.8 |
94 years |
≤7.0 |
≤8.7 |
= 95 years |
≤6.9 |
≤8.6 |
For SI unit Reference Values, see www.mayocliniclabs.com/order-tests/si-unit-conversion.html
Day(s) Performed
Monday through Friday
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
83497
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
HIAA | 5-Hydroxyindoleacetic Acid, U | 1695-6 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
9248 | 5-Hydroxyindoleacetic Acid, U | 1695-6 |
TM35 | Collection Duration | 13362-9 |
VL33 | Urine Volume | 3167-4 |
Interpretation
If pharmacological and dietary artifacts have been ruled out, an elevated excretion of 5-hydroxyindoleacetic acid is a probable indicator of the presence of a serotonin-producing tumor.
Clinical Reference
1. Grimaldi F, Fazio N, Attanasio R, et al. Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. J Endocrinol Invest. 2014;37(9):875-909. doi:10.1007/s40618-014-0119-0
2. Vinik A, Hughes MS. Feliberti E, et al. Carcinoid tumors. In: Feingold KR, Anawalt B, Boyce A, et al, eds. Endotext [Internet]. MDText.com Inc; 2000. Updated February 5, 2018. Accessed March 17, 2023. Available at www.ncbi.nlm.nih.gov/books/NBK279162/
3. Shah D, Mandot A, Cerejo C, Amarapurkar D, Pal A. The outcome of primary hepatic neuroendocrine tumors: A single-center experience. J Clin Exp Hepatol. 2019;9(6):710-715. doi:10.1016/j.jceh.2019.08.002
4. Perry D, Hayek SS. Carcinoid heart disease: A guide for clinicians. Cardiol Clin. 2019;37(4):497-503. doi:10.1016/j.ccl.2019.07.014
5. Degnan AJ, Tocchio S, Kurtom W, Tadros SS. Pediatric neuroendocrine carcinoid tumors: Management, pathology, and imaging findings in a pediatric referral center. Pediatr Blood Cancer. 2017;64(9). doi:10.1002/pbc.26477
6. Corcuff JB, Chardon L, El Hajji Ridah I, Brossaud J. Urinary sampling for 5HIAA and metanephrines determination: revisiting the recommendations. Endocr Connect. 2017;6(6):R87-R98. doi:10.1530/EC-17-0071
Report Available
2 to 4 daysMethod Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Forms
If not ordering electronically, complete, print, and send an Oncology Test Request (T729) with the specimen.
Aliases:
5-HIAA (5-Hydroxyindolacetic Acid)
5-OH-Indoleacetic Acid
Carcinoid Syndrome
HIAA (Hydroxyindoleacetic Acid)
Serotonin Metabolite
5HIAA